Interim Report 2026
Filed with HKEX · Stock code 950 · · 82 pages · English and Chinese
The Directors present herewith the unaudited consolidated interim financial results (the “Interim Results”) of the Group for the six months ended 30 June 2026, together with the comparative figures for the corresponding period in 2025. The Interim Results are unaudited, but have been reviewed by the Company’s auditor, Confucius International CPA Limited (the “Auditor”) in accordance with Hong Kong
Lee's Pharmaceutical Holdings Limited on 6ix
Earlier from Lee's Pharmaceutical
- Lee's Pharmaceutical Holdings: Connected Transaction - Provision of Financial Assistance
- Lee Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed from Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China
- - Grant of Share Options
- - Establishment of the Group Commercial Operations Centre
- - Business Update on the In-Licensing and Research and Development of Ophthalmology Products of an Associated Company of the Group
Later from Lee's Pharmaceutical
- Notification Letter and Reply Form to Registered Shareholders - Notice of Publication of Interim Report
- Notification Letter and Reply Form to Non-Registered Shareholders - Notice of Publication of Interim Report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Lee's Pharmaceutical into a list and get an email when it puts out news.
Follow Lee's Pharmaceutical